Company / Depreciation & Amortization
Aligos Therapeutics, Inc. Depreciation & Amortization History
FY2020-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$2.3M
FY2023
5-year range
$2.3M / $3.0M
FY2020-FY2023
Trend
-23.6%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $3M to $2M over the past 2 years.
Based on SEC 10-K filings.
$2M in FY2023 with a 3-year CAGR of +18.2%.
Improved from $3M to $2M over the past 2 years.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +18.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +18.2%, indicating consistent growth.
- In FY2023, depreciation & amortization decreased 23.6% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -8.07 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $2.3M | -23.6% |
| FY2022 | $3.0M | +10.4% |
| FY2021 | $2.7M | +95.9% |
| FY2020 | $1.4M | - |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026